FDA panel rejects Pfizer’s arthritis drug as too risky

The new antibody that may be able to stay ‘one step ahead’ of coronavirus mutations
25 March 2021
Pfizer begins COVID vaccine trial in young children
25 March 2021

FDA panel rejects Pfizer’s arthritis drug as too risky

U.S. health advisers sharply criticized an experimental arthritis drug Thursday, saying that it was too risky, even with limits on its use.

Comments are closed.